Fig. 6

Effect of 6G in CDX and PDX models. a and (b) 6G enhance the antitumor effect of cisplatin and inhibited the growth and metastasis in PLC/PRF/5 xenografts model (n = 8). **, P < 0.01, one-way ANOVA. c and (d) 6G enhanced the anti-tumor effect of cisplatin and reduce metastasis in Patient-derived xenograft (PDX) model (n = 8). **, P < 0.01, one-way ANOVA. e 6G combination of cisplatin increased the survival time of mice, while the anti-angiogenesis drugs sorafenib combination of cisplatin decreased survival time. f Inductively coupled plasma mass spectrometry (ICP-MS) analysis the distribution of metal platinum in various organs of mice. Results showed that 6G increased the content of metal platinum in tumor. While, sorafenib reduces the distribution of metal platinum in tumors, but increases the distribution of metal platinum in the liver, kidney and skin. Results represent the means of three experiments, and all values represent the means ± SEM. ^*P < 0.05, ^**P < 0.01